Expression of recombinant proteins in early and late stage discovery

During the last decades conventional treatment of complex diseases yields personalized medicine and biotherapeutics with persuasive clinical results and increasing approvals. Among monoclonal antibodies and enzymes innovative protein formats as fusion proteins or bispecific antibodies fill drug candidate pipelines. However, most candidates fail during pre-clinical development occasionally because of non-expressibility in mammalian cells, cost and time pressure, increasing regulatory requirements or disappointing results. Non-GMP transient gene expression is the method of choice to produce hundreds or thousands of molecules in a cost-efficient way before starting expensive and time-consuming stable cell line development. InVivo’s Expression System for transient Transfection (InVEST) is a state of the art expression platform meeting the demands of early and late stage drug discovery and development approaches. The platform allows the development of up to 240 candidates in small scale expressions (à 15 mL), up to 70 mid scale expressions (à 750 mL) or up to 6 large scale expressions (à 9 L) in less than 6 weeks after DNA delivery.

Click here for more information

Meet us at these conferences this year

InVivo will attend at following conferences:

  • AACC 2018 Congress in Chicago, IL: AACC 2018 is organizing their 70th Annual Scientific Meeting from 29 July to 2 Aug
  • Meet in Italy for Life Sciences 2018, 5th edition Brokerage Event in Bologna from 10 to 11 October 2018
  • HUMAN ANTIBODIES & HYBRIDOMAS  – HAH 2018 in Riga from 22 to 24 October 2018
  • 10th annual PEGS Europe: Protein & Antibody Engineering Summit in Lisbon, Portugal from 12 to 16 November 2018
  • MEDICA 2018 – World Forum for Medicine in Düsseldorf: the world’s leading trade fair for the medical industry. 12 to 15 November 2018, Düsseldorf, Germany. Booth 3C11

We look forward to meeting with you at an event to discuss your project in protein production. Write us an e-mail and schedule a meeting today.

Converting rabbit hybridoma into recombinant antibodies with effective transient production in an optimized human expression system

Mouse monoclonal antibodies are standard in research and diagnostic. Among all advantages of mouse monoclonal antibodies there is a lack of affinity, sensitivity and specificity especially for small epitopes and antigens that are non-immunogenic to rodents. This suggests that a huge number of diseases are under-diagnosed because of non-availability of high-quality antibodies. Rabbit monoclonal antibodies (Rab-mabs) show 10 to 100 times higher affinities than mouse monoclonal antibodies and impress by improved specificity which is extremely important in all fields of clinical and non-clinical diagnostic. However, all advantages of Rab-mabs are eliminated by the low productivity of monoclonal rabbit hybridoma. To meet the needs of IVD manufacturers InVivo implemented a rapid Rab-mab production system by transient gene expression to generate mg to g scales of highly affine, sensitive and specific IgGs within weeks.

Successful conversion of Rab-mabs into recombinant rabbit antibodies requires a combination of different scientific techniques. Firstly needed is the preparation of cDNA and sequencing of the antibody variable regions out of the rabbit hybridoma cell line. Second, synthesized full length rabbit antibody cDNA are cloned into mammalian expression vectors. Third, recombinant rabbit antibody is produced in mammalian cells preserving high productivity at good viability and suitable cell density. InVivo has implemented a novel technology for efficient transient transfection and expression in HEK cells, being especially designed for high-yielding recombinant antibody production. In brief, we developed a low cytotoxicity transfection reagent and a culture medium that can be used for transfection and production. For the establishment of an optimized host cell line for transient gene expression processes we utilized directed evolution. This completed the production platform for high throughput approaches and large scale transfection for the production of gram quantities IgG within days.

Dr. Tim Welsink presented workflow, optimization of expression and case study data on producing recombinant Rab-mabs at the HAH conference in November 2016. Click here for the final presentation as pdf

For more information about transient transfection and how to achieve the best results visit our website